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OBJECTIVE—The metabolism of hepatic- and intestinally derived
lipoproteins is regulated in a complex fashion by nutrients, hor-
mones, and neurologic and other factors. Recent studies in animal
models suggest an important role for glucagon acting via the glu-
cagon receptor in regulating hepatic triglyceride (TG) secretion.
Here we examined the direct effects of glucagon on regulation of
hepatic and intestinal lipoprotein metabolism in humans.
RESEARCH DESIGN AND METHODS—Eight healthy men
underwent two studies each, in random order, 4–6 weeks apart
in which de novo lipogenesis, kinetics of larger VLDL1 TG, and
kinetics of VLDL1 and smaller VLDL2 apolipoprotein (apo)B100
and B48 were studied using established stable isotope enrich-
ment methods. Subjects were studied in the constant fed state
under conditions of a pancreatic clamp (with infusion of somato-
statin, insulin, and growth hormone) at either basal glucagon (BG
study, 64.5 6 2.1 pg/mL) or hyperglucagonemia (high glucagon
[HG] study, 183.2 6 5.1 pg/mL).
RESULTS—There were no signiﬁcant differences in plasma
concentration of VLDL1 or VLDL2 TG, apoB100 or apoB48
between BG and HG studies. There was, however, lower (P ,
0.05) VLDL1 apoB100 fractional catabolic rate (239%) and pro-
duction rate (230%) in HG versus BG, but no difference in de
novo lipogenesis or TG turnover, and glucagon had no effect on
intestinal (B48-containing) lipoprotein metabolism.
CONCLUSIONS—Glucagon acutely regulates hepatic but not
intestinal lipoprotein particle metabolism in humans both by
decreasing hepatic lipoprotein particle production as well as by
inhibiting particle clearance, with no net effect on particle
concentration. Diabetes 60:383–390, 2011
D
yslipidemia is a well-recognized characteristic
of insulin-resistant states and type 2 diabetes
and contributes to the development of ath-
erogenic cardiovascular disease (1,2). Hyper-
triglyceridemia, low HDL cholesterol, and increased small,
dense LDL particles are typical features of dyslipidemia
in insulin resistance and type 2 diabetes (1). Both he-
patic (apolipoprotein [apo]B100-containing) and intestinal
(apoB48-containing) lipoproteins are increased in insulin
resistance and type 2 diabetes (1–5). Increased production
of both hepatic and intestinal lipoproteins as well as
impairment in particle clearance contributes to the ele-
vated plasma concentrations (1,6–10).
The mechanisms whereby hepatic and intestinal lipo-
protein production is regulated are not clearly understood.
In animal models (rev. in [6]) and humans (9–14), produc-
tion of these particles is subject to substrate supply and
hormonal regulation; thus free fatty acids (FFAs) stimulate
and acute hyperinsulinemia suppresses hepatic and intes-
tinal lipoprotein production (9,10,12–15). Whereas defects
of insulin secretion and action and elevation of plasma
FFAs are well described abnormalities of type 2 diabetes,
less appreciated is the dysregulation of glucagon secretion
that is also present in diabetes (16,17). Although fasting
concentrations of glucagon in diabetic patients are usually
similar to those in nondiabetic subjects, suppression of
glucagon after glucose ingestion is impaired in type 2 di-
abetic patients (16). Postprandial hyperglucagonemia may
play an important role in the dysregulation of carbohydrate
and lipid metabolism in type 2 diabetes, and suppression of
glucagon action has been proposed as a therapeutic ap-
proach to the treatment of type 2 diabetes (18,19). Recently,
glucagon signaling through the glucagon receptor (Gcgr)
has been shown to be essential for control of hepatic lipid
homeostasis in mice (20). Although several studies in ani-
mals have indicated that chronic exogenous glucagon
treatment may exert hypolipidemic effects (20–22), modu-
lation of the Gcgr has yielded conﬂicting results (20,23).
Because of potential confounding factors in chronic studies,
the direct role of glucagon in regulating hepatic and in-
testinal lipoprotein metabolism is not clear, nor has this
been directly examined in humans.
The objective of the current study, therefore, was to
investigate the effect of acute hyperglucagonemia on he-
patic and intestinal lipoprotein metabolism in healthy
humans. Because infusion of glucagon affects the secre-
tion of other pancreatic hormones such as insulin, which is
known to exert independent effects on lipoprotein me-
tabolism, studies were performed under conditions of a
pancreatic clamp. Because we were interested in exam-
ining both intestinal as well as hepatic lipoprotein metab-
olism and it is technically difﬁcult to measure intestinal
lipoprotein production rates in fasted humans, studies
were conducted in the constant fed state.
RESEARCH DESIGN AND METHODS
Subjects. Eight healthy, normolipidemic men participated in this study. Their
demographic characteristics and fasting biochemical proﬁles are shown in
Table 1. None of the participants had any previous history of cardiovascular
disease, gastrointestinal or systemic illness, or surgical intervention within
6 months before the studies. No subject was taking medications, and all had
normal oral glucose tolerance tests performed immediately before enrollment
in the study. The Research Ethics Board of the University Health Network,
University of Toronto, approved the study, and all subjects gave written in-
formed consent before their participation.
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ORIGINAL ARTICLEExperimental protocol for lipoprotein kinetic studies. Each subject un-
derwent two separate lipoprotein kinetic studies in random order, 4 to 6 weeks
apart (Fig. 1A). In each study, two intravenous catheters were inserted, one
into a superﬁcial vein in each forearm, for infusion and for blood sampling,
respectively. At 3 P.M., a constant infusion of sodium 1-
13C-acetate (15 gm/L at
32 mL/h; Cambridge Isotope Laboratories, Andover, MA) was started for as-
sessment of de novo lipogenesis (24,25). Subjects were fasted after a mixed
meal at 5 P.M.. Starting at 4 A.M. the next day, a liquid formula (Hormel Great
Shake Plus, Hormel Health Laboratories, Savannah, GA; total fat 10% by
weight, saturated fat 1.5%, trans fat 0%, monounsaturated fat 2.6%, poly-
unsaturated fat 5.6%, cholesterol 0%; 49% calories from fat, 38% from carbo-
hydrates, 13% from proteins) was ingested hourly for the ﬁrst 3 h and every
half hour thereafter to achieve a constant fed state. Each aliquot was calcu-
lated to evenly spread the total daily caloric requirement across the course of
the study. The Harris-Benedict equation was used to estimate the total daily
energy requirement for each subject. Kinetic studies were performed in the
constant fed state because apoB48 levels are too low in the fasted state to
allow accurate assessment of isotopic enrichments.
At 7 A.M., i.e., 3 h after starting the liquid formula, a pancreatic clamp was
started with the following infusion rates: 30 mg/h somatostatin (Sandostatin,
Norvatis Pharmaceuticals Canada, Dorval, QC, Canada), 0.05 mU/kg/min in-
sulin (Humulin R, Eli Lilly Canada, Toronto, ON, Canada), 3 ng/kg/min human
recombinant growth hormone (Humatrope, Eli Lilly), and 20% dextrose as
required in a few subjects towards the end of the study at a variable rate to
maintain euglycemia. Glucagon (Eli Lilly Canada) was infused at different
rates in each of the two separate studies to achieve either basal glucagon (BG;
0.65 ng/kg/min) or high glucagon (HG; 3 ng/kg/min) circulating glucagon lev-
els. All hormones were diluted in 1 L of half-strength normal saline and infused
with a syringe pump (B. Braun Medical, Bethlehem, PA). Autologous serum (5
mL), freshly prepared from the subject’s blood, was added to the saline as
carrier before hormone dilution.
Six hours after starting the liquid formula ingestion and 3 h after starting
the pancreatic clamp, subjects received a bolus of [1,1,2,3,3-
2H5]-glycerol
(d5-glycerol, 75 mmol/kg; Cambridge Isotope Laboratories) and a primed, constant
infusion (10 µmol/kg bolus followed by 10 mmol/kg/h for 10 h) of L-[5,5,5-
2H3]-
leucine (d3-leucine; Cambridge Isotope Laboratories) for assessment of tri-
glyceride (TG) and lipoprotein kinetics, respectively, as previously described
(26–28). After the start of the d3-leucine infusion, blood samples were col-
lected at 1, 3, 5, 7, 9, and 10 h for isolation of lipoproteins. Blood samples for
TABLE 1
Demographic characteristics and fasting biochemical parameters
of subjects (n =8 )
Characteristic Mean 6 SE Range
Age (years) 41.3 6 3.0 30–55
Weight (kg) 70.9 6 3.5 59.0–87.0
BMI (kg/m
2) 22.5 6 0.6 20.0–25.6
Glucose (mmol/L) 5.4 6 0.2 4.8–6.3
Insulin (pmol/L) 47.5 6 6.8 17.4–81.0
Glucagon (pg/mL) 69.1 6 6.5 47.1–100.5
Plasma (mmol/L)
FFA 0.23 6 0.04 0.11–0.44
TG 1.03 6 0.11 0.63–1.60
Total cholesterol 4.02 6 0.17 3.50–4.76
VLDL
1 ApoB48 (mg/L) 0.65 6 0.17 0.14–1.72
1 ApoB100 (mg/dL) 2.15 6 0.36 1.08–3.75
2 ApoB48 (mg/L) 0.85 6 0.15 0.20–1.35
2 ApoB100 (mg/dL) 2.67 6 0.40 1.41–5.06
3P.M. 5P.M. 4A.M. 7A.M. 10A.M. 8P.M.
FIG. 1. Study protocol (A) and plasma concentrations of glucose (B), insulin (C), and glucagon (D) over the time course of the study. A constant
infusion of sodium 1-
13C-acetate was started at 3 P.M. on the day before the kinetics study. A mixed meal was provided that day at 5 P.M., after which
the subject fasted. At 4 A.M. the next day subjects started to ingest identical hourly, then half hourly, volumes of a liquid high fat nutritional
supplement to maintain a constant fed state. At 7 A.M., i.e., 3 h after starting to ingest the formula, a pancreatic clamp was started with infusion of
somatostatin, insulin, growth hormone, and glucagon, the latter to achieve either BG (□)o rH G( ◆) plasma concentrations. At 10 A.M. (referred to
as time 0 for the lipoprotein kinetic study), i.e., 3 h after starting the pancreatic clamp, a bolus of [1,1,2,3,3-
2H5]-glycerol (d5-glycerol) was ad-
ministered and a primed, constant infusion of L-[5,5,5-
2H3]-leucine (d3-leucine) was started and continued for 10 h (A). Plasma glucose (B) and
insulin (C) concentrations were similar in BG and HG studies, whereas glucagon (D) was approximately threefold higher in HG vs. BG. *P < 0.0001
HG vs. BG.
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described (9). At the end of the kinetic study, a bolus of heparin sodium (60
i.u./kg, Baxter Pharmaceuticals, Mississauga, ON, Canada) was injected. Blood
samples (5 mL) were collected after 10 min into EDTA tubes on ice, and
plasma was separated immediately and stored at 280°C until performance of
lipase assays.
Laboratory methods. VLDL1 and VLDL2 fractions were isolated from fresh
plasma using cumulative ﬂotation gradient ultracentrifugation (29). In brief,
plasma was adjusted to d = 1.10 g/mL with NaCl. A discontinuous density
gradient consisting of 4 mL of d =1 . 1 0g / m Lo fp l a s m a ,3m Lo fd = 1.063 g/mL,
3m Lo fd = 1.019 g/mL, and 2.8 mL of d = 1.006 g/mL NaCl solution was
created. Samples were then centrifuged at 40,000 revolutions per min at
4°C in a Ti40 SW rotor (Beckman, Palo Alto, CA). Consecutive runs were
performed to separate fractions that correspond to chylomicron (Sf . 400,
38 min), VLDL1 (Sf 60–400, 3 h 28 min), and VLDL2 (Sf 20–60, 17 h). After
each step 1 mL of the gradient containing speciﬁc lipoprotein fraction was
aspirated and 1 mL of d =1 . 0 0 6g / m Lw a su s e dt or e ﬁll the tubes before the
next run.
Aliquots of VLDL fractions (;1 mg protein) were delipidated and separated
by preparative 3.3% SDS-PAGE. Gel bands corresponding to apoB48 and
apoB100 were excised and hydrolyzed, and amino acids were derivatized to
allow for the determination of plasma leucine isotopic enrichment as de-
scribed (8). Brieﬂy, gel bands were incubated at 110°C with 6N HCl for 24 h,
dried under vacuum before being derivatized with 100 µL mixture (1:1) of
acetonitrile: N-tert-butyldimethyl-N-methyltriﬂuoracetamide (Sigma-Aldrich).
Plasma free amino acids were recovered from 0.25 mL plasma after pre-
cipitation of proteins with acetone and extraction of the aqueous phase with
hexane (30). The aqueous phase was dried under vacuum, amino acids were
derivatized, and enrichments were determined as above. Derivatized samples
were analyzed by electron impact ionization gas chromatography–mass
spectrometry (GCMS; Agilent 5975/6890N, Agilent Technologies Canada,
Mississauga, ON, Canada) using helium as the carrier gas. Selective ion
monitoring at m/z = 200 and 203 was performed, and tracer-to-tracee ratios
were calculated from isotopic ratios for each sample according to a standard
curve of isotopic enrichment.
VLDL1 fractions during the time course of the lipoprotein kinetic study
(0–10 h) were processed for estimation of VLDL-TG and glycerol turnover,
as previously described (26). Brieﬂy, deproteinized VLDL1 fractions were
separated on thin layer chromatography (TLC) plates and TLC scraping cor-
responding to TGs were collected. Lipids were extracted and dried, and fatty
acid methyl esters (FAMEs) were prepared. FAMEs were dissolved in hep-
tane, and the molecular ions of palmitate methyl ester were monitored on GCMS
at m/z = 270 and 272. Glycerol was derivatized with 100 mL 33% hepta-
ﬂuorobutyric anhydride (HFB) anhydrate in ethyl acetate (HFBA: ethyl acetate =
1:2, vol/vol). Ions of HFB-glycerol were monitored at m/z = 467 and 472.
Commercial kits were used to measure cholesterol (Roche Diagnostics,
Mannheim, Germany), TG (Roche Diagnostics), FFA (Wako Industrials, Osaka,
Japan), insulin (Millipore, Billerica, MA), and glucagon (Millipore). ApoB100
was separated by 3–8% SDS-PAGE and quantiﬁed using an LDL apoB100
standard as previously described (31). ApoB48 mass was measured using
a human apoB48 ELISA kit (Shibayagi, Shibukawa, Gunma, Japan). Lipopro-
tein lipase and hepatic lipase activities in postheparin plasma were measured
using a triolein emulsion containing radiolabeled triolein as previously de-
scribed (32).
Kinetic analysis. Stable isotope enrichment curves for apoB48 and apoB100
wereﬁttedtoamulticompartmentalmodelusingSAAMIIsoftware(version1.2,
UniversityofWashington,Seattle,WA)toestimatethefractionalcatabolicrates
(FCR) of VLDL1 and VLDL2 apoB48 or VLDL1 and VLDL2 apoB100, as pre-
viously described (10). The model consisted of synthesis of both VLDL1 and
VLDL2 apoB from the precursor pool via a delay compartment, as well as
conversion from VLDL1 to VLDL2. Individual enrichment (tracer to tracee
ratios) and apoB masses were used to derive kinetic rate constants, which
were independent for the two subsystems. Plasma leucine enrichment was
used as a forcing function. FCR of VLDL1 was the sum of the conversion from
VLDL1 to VLDL2 and direct loss from the VLDL1 compartment. Production
rates (PR) of each apolipoprotein were calculated as the FCR multiplied
by pool size, where pool size equaled average plasma concentration (in
mg/L) between 1 and 10 h of the kinetic study 3 plasma volume (estimated
as 0.045 L/kg body wt).
The monoexponential slopes of VLDL1-TG glycerol stable isotope enrich-
ment curves were determined from the peak of the isotopic enrichment to the
end of the kinetic study (usually between 2 and 10 h), on the log-linear portion
of the curve (26). This approach, when compared with compartmental mod-
eling, might slightly underestimate the FCR of VLDL-TG. However, any po-
tential bias due to the choice of method should be similar to each treatment arm
and not affect the conclusion of the study. De novo synthesis of VLDL1-TG
FIG. 2. Plasma TG (A), plasma FFA (B), VLDL1-TG (C), and VLDL2-TG (D) over the time course of the lipoprotein kinetic study in subjects
receiving either BG (□)o rH G( ◆) infusion rate during pancreatic clamp. N =8 .P = NS HG vs. BG for all parameters.
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VLDL1-TG palmitate pool was calculated as average VLDL1-TG concentration
during the lipoprotein kinetic study 3 plasma volume (0.045 L/kg body wt), and
percentage of newly synthesized palmitate in VLDL1-TG was used to illustrate
de novo lipogenesis.
Statistics. Results are presented as mean 6 SE. Repeated-measures ANOVA
was used to compare the time course of parameters during the kinetic
experiments. Paired t test was used to compare FCR and PR of lipoprotein and
TG and de novo lipogenesis between the two treatments. All statistics were
performed with SAS (version 8, Cary, NC). A P value ,0.05 was considered
signiﬁcant.
RESULTS
Pancreatic clamp. During the pancreatic clamp, levels of
plasma glucose transiently increased approximately two-
fold but returned toward baseline after 4 h and remained
;1.5-fold elevated for the duration for the study. Glucose
was well matched between treatment arms (Fig. 1B).
Plasma insulin levels were maintained at basal after an
initial increase and were similar in both treatment arms of
the study (Fig. 1C). Plasma growth hormone levels (not
illustrated) rose from basal but were closely matched be-
tween treatment arms (0.40 6 0.10 mg/L in BG and 0.49 6
0.15 mg/L in HG at basal, 1.15 6 0.12 mg/L in BG and 1.17 6
0.10 mg/L in HG in clamp). Plasma glucagon levels were
maintained at basal in BG (Fig. 1D). In contrast, in the HG
arm there was a signiﬁcant threefold elevation of circu-
lating glucagon concentration (183.2 6 5.1 pg/mL in HG vs.
64.5 6 2.1 pg/mL in BG, P , 0.0001), which was main-
tained for 13 h.
Effects of acute hyperglucagonemia on plasma TG,
FFA, and VLDL-TG, and apoB48 and apoB100 con-
centrations. Plasma TG (Fig. 2A) and FFA (Fig. 2B) did
not differ between BG and HG studies throughout the
study. In both VLDL1 (Fig. 2C) and VLDL2 (Fig. 2D) frac-
tions, TG concentrations were similar between BG and HG
studies. ApoB48 and apoB100 in both VLDL fractions
remained constant for the duration of the lipoprotein ki-
netics study and did not differ between BG and HG studies
(Fig. 3, A–D). The levels of TG, apoB48, and apoB100 in
plasma and VLDL fractions and FFAs in plasma during the
lipoprotein kinetic study were not signiﬁcantly different
from the basal levels (before the pancreatic clamp).
Effects of acute hyperglucagonemia on VLDL apoB48
and apoB100 fractional catabolic rates and production
rates. Fractional catabolic rates of VLDL1 and VLDL2
apoB48 were not signiﬁcantly different between BG and
HG studies (Fig. 4A). Similarly, PRs of apoB48 in both VLDL
fractions were similar in BG and HG (Fig. 4B). In contrast,
the FCR of VLDL1 apoB100 was 39% lower in HG (6.1 6 1.0
pools/day) vs. BG (10.0 6 1.7 pool/day) (P , 0.01) (Fig. 4C).
A similar magnitude of reduction in PR was observed for
VLDL1 apoB100 in HG vs. BG (6.4 6 1.9 vs. 9.2 6 1.8 mg/kg/
day, P , 0.05) (Fig. 4D). The trend was similar for apoB100
FCR and PR in VLDL2, although these parameters did not
reach statistical signiﬁcance (FCR = 8.7 6 1.7 vs. 11.3 6 1.8
pool/day, P =0 . 0 8 ;P R=1 1 . 16 1.8 vs. 14.9 6 1.2 mg/kg/day,
P = 0.1). The similar VLDL apoB100 concentrations in Fig. 3B
and D were thus explained by the simultaneous reduction
FIG. 3. VLDL1 apoB48 (A), VLDL1 apoB100 (B), VLDL2 apoB48 (C), and VLDL2 apoB100 (D) over the time course of the lipoprotein kinetic study
in subjects receiving either BG (□)o rH G( ◆) infusion rate during pancreatic clamp. Conc, concentration. N =8 .P = NS HG vs. BG for all
parameters.
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plasma pool size. A further analysis of the source of VLDL2
apoB100 production indicates that the differences were
mainly due to production via VLDL1 (HG 6.4 6 1.9 vs. BG
9.2 6 1.8 mg/kg/day, P , 0.05) but not direct production
(HG 4.7 6 1.1 vs. 5.5 6 1.3 mg/kg/day, P = NS).
Effects of acute hyperglucagonemia on de novo
lipogenesis, VLDL1-TG turnover, and postheparin
lipase activities. As indicated in Fig. 5A, newly synthe-
sized palmitate from acetate in VLDL1-TG was not differ-
ent between BG and HG study arms. Fractional catabolic
rates and PR of VLDL1-TG also did not differ between BG
vs. HG (Fig. 5, B and C, respectively). Postheparin lipase
activities (not illustrated) were not signiﬁcantly different
between BG (20 6 12 and 35 6 8 nmol/min/mg for lipo-
protein lipase and hepatic lipase, respectively) and HG
(34 6 15 and 41 6 10 nmol/min/mg for lipoprotein lipase
and hepatic lipase, respectively).
DISCUSSION
Because glucagon affects numerous aspects of metabolism
that could in turn have direct or indirect effects on lipo-
protein metabolism, the direct role of glucagon in lipid and
lipoprotein metabolism remains unclear. The current study
is the ﬁrst to examine the direct role of short-term eleva-
tion of glucagon, under the condition of pancreatic clamp
and in the fed state, on hepatic and intestinal lipoprotein
metabolism in humans. We have shown in this study that
acute hyperglucagonemia, in a controlled experimental
setting in which other hormone levels and circulating
metabolites are well matched between studies, does not
affect plasma concentrations of apoB-containing intestinal
and hepatic lipoproteins and does not affect the rate of de
novo lipogenesis or TG metabolism but does impair both
the clearance and PR of larger (VLDL1) hepatically derived
lipoproteins.
Glucagon plays a key role in carbohydrate (33–35) and
lipid homeostasis (20), and postprandial hyperglucagonemia
likely contributes to many of the metabolic defects of type 2
diabetes, with suppression of glucagon action being pro-
posed as a therapeutic approach to the treatment of type 2
diabetes (18,19). Chronic administration of exogenous glu-
cagon in animals generated hypolipemidemic effects, with
reduced plasma TG, FFA, and cholesterol; decreased VLDL
secretion from the liver; increased hepatic fatty acid (FA)
oxidation; and decreased hepatic accumulation of lipid
(21,36–38). Glucagon decreased plasma FFAs and VLDL-TG
and prevented fatty liver in dairy cows receiving daily
injections of glucagon for 2 weeks (21,39,40). In rats re-
ceiving daily injections of glucagon for 8 or 21 days, TG in
chylomicron and VLDL (22,37,41) and plasma cholesterol
concentrations were decreased (36,37). On the other hand,
genetic ablation of the Gcgr in mice increased circulating
TG and FFAs after fasting, whereas administration of glu-
cagon for 24 h produced the opposite effects (20). Gcgr
2/2
mice had increased plasma and hepatic TG (20) and were
resistant to hepatic accumulation of lipid (42). However,
reduced Gcgr expression with antisense oligonucleotide in
db/db mice for 3 weeks decreased circulating TG and FFAs
(23). Longuet et al. (20) recently showed that Gcgr
signaling is essential for regulation of hepatic lipid ho-
meostasis. When compared with wild-type (WT) litter-
mates, Gcgr
2/2 mice had increased plasma TG and hepatic
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FIG. 4. Effect of acute hyperglucagonemia on VLDL apoB FCR (A and C) and PR (B and D) in subjects receiving either BG (white bar) or HG
(hatched bar) infusion rate during pancreatic clamp. N = 8. The only signiﬁcant differences were a lower FCR and PR for VLDL1-apoB100 in HG vs.
BG. *P < 0.05 HG vs. BG.
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of glucagon over 24 h decreased plasma TG and FFAs in WT
mice. Acute, single dose injection of glucagon also decreased
TG secretion in WT mice. During fasting, glucagon, acting via
the Gcgr, stimulated peroxisome proliferator–activated re-
ceptor (PPAR-a) activity in a p38 mitogen-activated protein
kinase (MAPK)- and AMP-activated protein kinase (AMPK)-
dependent manner, subsequently diverting more FA for
b-oxidation instead of TG synthesis, thus reducing hepatic
TG accumulation. Glucagon also decreased hepatic TG se-
cretion independent of PPAR-a activation and FA b-oxidation
(20). It is important to be cognizant of the fact that in
chronic studies potential confounding effects due to com-
pensatory secretion of other hormones, such as insulin, and
changes in plasma FFA and glucose concentrations, cannot
be ruled out. Indeed, concomitant increase of insulin was
detectable in dairy cows after glucagon injection, at least
transiently (39).
In the current study we administered glucagon under
pancreatic clamp conditions to generate a threefold ele-
vation of circulating glucagon above basal. Fasting gluca-
gon concentrations in healthy subjects are ;100 pg/mL
(16). In obese nondiabetic subjects, plasma glucagon con-
centration was reported as ;70 pg/mL in the postabsorptive
state and increased to 100–144 pg/mL during prolonged fast-
ing (43). The level of hyperglucagonemia achieved in the
current study is within the reported range of various studies
with glucagon infusion (17,34,44). This degree of hyper-
glucagonemia was maintained for 12 h with the levels of in-
sulin, glucose, FFAs, and growth hormone well matched
between the two experimental arms of the study. Thus the
above-mentioned potential confounding factors were ex-
cluded. To be able to assess apoB48 stable isotope enrich-
ment with a high degree of precision, subjects were
maintained in a constant fed state to stimulate intestinal
lipoprotein production. Under these conditions, we found
that hyperglucagonemia decreased the production of large,
hepatically derived, VLDL1 lipoprotein particle production
(with a nonsigniﬁcant similar trend in smaller VLDL2). The
reduction in apoB100-containing lipoprotein production was
accompanied by a reduction in particle clearance of similar
magnitude, leading to unchanged circulating VLDL apoB100
concentration (i.e., particle pool size). No signiﬁcant effects
of hyperglucagonemia were observed on intestinal lipopro-
tein metabolism, de novo lipogenesis, or TG turnover.
Very limited information is available regarding glucagon
effects on hepatic lipoprotein production. Guettet et al. (22)
reported that exogenous glucagon (twice daily injection for
21 days) increased clearance of TG-rich lipoprotein in high-
sucrose fed rats. In an acute study with glucagon in dogs,
2-h glucagon infusion decreased removal of Intralipid (45).
The mechanism whereby hyperglucagonemia decreases
FCR of hepatic lipoprotein particles is not known. Although
glucagon might affect lipase activities (46), postheparin li-
poprotein lipase and hepatic lipase activities were assessed
at the end of our study and were not signiﬁcantly affected
by HG infusion. Therefore, the reduction in FCR could not
be explained by reduction in lipase activities. In cultured
rat hepatocytes, 24-h treatment with glucagon increased
LDL binding to its receptor and promoted degradation (47).
Although glucagon has been shown to activate PPAR-a in
rodent hepatocytes (20), PPAR-a agonist ﬁbrates reduce
VLDL-apoB100 through enhancing clearance and decreas-
ing production in hyperlipemic patients (48). The observed
effects of hyperglucagonemia on hepatic lipoprotein parti-
cle production in the current study thus may not be attrib-
uted to its effects on PPAR-a. The impact of reduced
hepatic lipoprotein particle turnover is not clear and needs
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FIG. 5. Effect of acute hyperglucagonemia on de novo lipogenesis (A), VLDL1-TG FCR (B), and PR (C) in subjects receiving either BG (white bar)
or HG (hatched bar) infusion rate during pancreatic clamp. VLDL apoB FCR and PR are shown. %DN V1-C16:0, percentage of newly synthesized
palmitate in VLDL1-TG. There were no signiﬁcant differences for any of the parameters illustrated.
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in the intestine (49), its physiological role in the intestine is
largely unknown. In the current study, intestinal lipoprotein
production was not affected by acute hyperglucagonemia,
suggesting lack of a direct role of glucagon in regulating
intestinal lipoprotein production in healthy humans.
The mechanism whereby glucagon differentially regu-
lates the clearance of lipoprotein particles from hepatic
and intestinal origins remains unclear. Clearance of apoB-
containing particle involves both receptor-dependent and
-independent pathways. Because postheparin lipase activities
were not signiﬁcantly affected by glucagon levels in this study
and it is generally accepted that intravascular lipolysis of
apoB100- and apoB48-containing lipoprotein particles share
common pathways, it is more likely that the regulation points
reside in the pathways involving interaction of lipoprotein
particles with cell surface receptors. LDL receptor is known
to mediate apoB-containing lipoprotein metabolism (50)
and is subject to regulation by glucagon in rats (47,51).
Whether glucagon, under the current study conditions, dif-
ferentially affects binding, uptake, and degradation of
apoB100- versus apoB48- containing lipoprotein particles
via the LDL receptor pathway warrants further study.
In conclusion, the current study does not support a role
for glucagon in regulating intestinal lipoprotein pro-
duction, in contrast with our previous studies, which have
shown that insulin and FFAs are important regulators of
both intestinal and hepatic lipoprotein production
(9,10,14). Similarly, acute hyperglucagonemia does not
affect de novo lipogenesis or lipoprotein TG metabolism.
In contrast, there is a very consistent effect of acute
hyperglucagonemia in suppressing the production of large,
hepatically derived, apoB100-containing lipoproteins in
humans, but this effect is offset by a reduction of similar
magnitude in the clearance of the particles. Because
hyperglucagonemia does not affect plasma concentrations
of apoB100-containing lipoproteins, glucagon appears to
have a less signiﬁcant role than either insulin or FFAs in
regulating hepatic lipoprotein production. The mechanism
of its effect on apoB100-containing particle production and
clearance remains to be determined. Because relative
postprandial hyperglucagonemia occurs in diabetic and
insulin-resistant individuals who usually also exhibit
hyperinsulinemia, future studies in this population may
provide more physiological and clinical relevance.
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